文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症中铁代谢失调:病因与后果

Dysregulated iron metabolism in polycythemia vera: etiology and consequences.
PubMed 文献 · Leukemia · 2018-07-24

真性红细胞增多症(PV)患者几乎均存在铁缺乏。本综述讨论PV中铁缺乏的临床后果,构建铁代谢失调的理解框架,并为铁缺乏PV患者提供额外治疗选择的理论依据。

要点

  • PV患者就诊时和/或病程中几乎均存在铁缺乏。
  • 铁缺乏程度下铁调素抑制不足,提示铁代谢紊乱是PV病理生物学的重要组分。
  • 治疗性静脉放血使血细胞比容正常化会加重铁缺乏,导致多种非血液学症状。

核心结论

  • PV患者铁缺乏程度下铁调素抑制不足,强烈提示铁代谢紊乱是PV病理生物学的重要组分。

研究设计与样本

  • 综述,围绕PV铁代谢失调的病因与后果进行综合讨论。

主要发现

  • PV患者就诊时和/或病程中几乎均存在铁缺乏,铁缺乏与红细胞增多并存呈现生理学上的割裂。
  • PV中红系增生导致循环铁降低和红铁酮(erythroferrone)升高,预期可抑制铁调素并 enabling 铁缺乏恢复。
  • PV伴随的炎症可能抵消铁调素抑制,但观察到的血清铁蛋白水平相对较低提示炎症并非铁代谢失调的主要 contributor。
  • PV患者铁吸收潜在缺陷、异常缺氧感知与信号传导以及出血频率对铁缺乏的作用尚未完全阐明。

临床怎么用

  • 治疗性静脉放血使血细胞比容正常化是降低血栓并发症发生率的最常用方法,该疗法加重铁缺乏并导致多种非血液学症状。
  • 高危PV患者使用细胞减灭治疗,在铁缺乏患者中逆转PV相关症状的效果常优于铁充足患者。

局限性

  • PV患者铁吸收潜在缺陷、异常缺氧感知与信号传导以及出血频率对铁缺乏的作用尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm. Virtually all PV patients are iron deficient at presentation and/or during the course of their disease. The co-existence of iron deficiency and polycythemia presents a physiological disconnect. Hepcidin, the master regulator of iron metabolism, is regulated by circulating iron levels, erythroblast secretion of erythroferrone, and inflammation. Both decreased circulating iron and increased erythroferrone levels, which occur as a consequence of erythroid hyperplasia in PV, are anticipated to suppress hepcidin and enable recovery from iron deficiency. Inflammation which accompanies PV is likely to counteract hepcidin suppression, but the relatively low serum ferritin levels observed suggest that inflammation is not a major contributor to the dysregulated iron metabolism. Furthermore, potential defects in iron absorption, aberrant hypoxia sensing and signaling, and frequency of bleeding to account for iron deficiency in PV patients have not been fully elucidated. Insufficiently suppressed hepcidin given the degree of iron deficiency in PV patients strongly suggests that disordered iron metabolism is an important component of the pathobiology of PV. Normalization of hematocrit levels using therapeutic phlebotomy is the most common approach for reducing the incidence of thrombotic complications, a therapy which exacerbates iron deficiency, contributing to a variety of non-hematological symptoms. The use of cytoreductive therapy in high-risk PV patients frequently works more effectively to reverse PV-associated symptoms in iron-deficient relative to iron-replete patients. Lastly, differences in iron-related parameters between PV patients and mice with JAK2 V617F and JAK2 exon 12 mutations suggest that specific regions in JAK2 may influence iron metabolism by nuanced changes of erythropoietin receptor signaling. In this review, we comprehensively discuss the clinical consequences of iron deficiency in PV, provide a framework for understanding the potential dysregulation of iron metabolism, and present a rationale for additional therapeutic options for iron-deficient PV patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018. PMID: 30042411. doi:10.1038/s41375-018-0207-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。